Biotech | January 08, 2022
Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
_256_275.jpeg)
